Financial Information | Regeneron Pharmaceuticals Inc.

Filing date	Form	Description	View
May 18, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001883850-22-000046.pdf 0001883850-22-000046.xls
May 11, 2022	SC TO-T/A	Amendment to a previously filed SC TO-T	View HTML 0001104659-22-058856.pdf 0001104659-22-058856.xls
May 04, 2022	8-K	Report of unscheduled material events or corporate event	View HTML 0001804220-22-000013.pdf 0001804220-22-000013.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 04, 2022	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001804220-22-000015.pdf 0001804220-22-000015.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 03, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001883850-22-000043.pdf 0001883850-22-000043.xls
May 03, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001883850-22-000044.pdf 0001883850-22-000044.xls
May 02, 2022	SC TO-T	Tender offer schedule and amendment filed by a third party.	View HTML 0001104659-22-054147.pdf 0001104659-22-054147.xls
Apr 21, 2022	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	View HTML 0000930413-22-000787.pdf 0000930413-22-000787.xls
Apr 21, 2022	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000930413-22-000789.pdf 0000930413-22-000789.xls
Apr 21, 2022	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000930413-22-000790.pdf 0000930413-22-000790.xls

Data provided by Kaleidoscope.

Investors & Media